摘要
AbstractThe coronavirus disease 2019 (COVID-19) outbreak affects the use of biologics for psoriatic patients, in the way that the consequential immunosuppression potentially alters a patient’s susceptibility to the virus or deteriorate the condition if the patient is infected or even change the prognosis of infection. Therefore, authors reviewed currently available recommendations from international psoriasis academic organizations and specialists, and summarized them with the specific situation in China. We are trying to provide guidance to the use of biologics for psoriatic patients in the following contexts: patients on biologic therapy, patients being considered for biologic therapy initiation, patients with low-risk or high-risk of SARS-CoV-2 coronavirus infection, patients tested negative or positive for the nucleic acid testing of virus.
机构地区
Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710032, China,Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences, Nanjing, Jiangsu 210042, China,Department of Dermatology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310009, China,Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China,Department of Dermatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200000, China,Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China,Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong 518053, China,Department of Dermato
出版日期
2020年08月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
